Back to School: How biopharma can reboot drug development. Access exclusive analysis here

tgAAC94 AAV2/TNFR:Fc: Restarted Phase I/II

FDA lifted the clinical hold on a Phase I/II trial of tgAAC94 to treat inflammatory arthritis that had been in

Read the full 209 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE